Navigation Links
InVitria Presents Zap-CHO Performance Results at PEACe Conference
Date:9/23/2009

Zap-CHO: a new and innovative CHO cell culture supplement from InVitria designed to deliver superior growth, maximum antibody productivity and faster cell line development. Performance results were presented to attendees of the PEACe Conference in Jackson Hole, WY this week.

Fort Collins, CO (PRWEB) September 23, 2009 -- A new powerful and robust cell culture supplement for CHO (Chinese hamster ovaries) cell line enhancement called Zap-CHO was featured this week at the 9th Protein Expression in Animal Cells (PEACe) Conference in Jackson Hole, Wyoming.

"Zap-CHO is a significant breakthrough in mammalian cell culture systems," said Dr. Steve Pettit, InVitria's Director of Cell Culture Development. "With the development of Zap-CHO, InVitria has created a performance enhancing CHO media supplement that is the first animal free supplement capable of replacing fetal bovine serum (FBS) without sacrificing performance and maintaining a well defined media. Since Zap-CHO is a defined and animal component-free product, it is well suited for commercial, chemically-defined and serum- and animal-free cell culture media formulations," said Dr. Pettit.

Dr. Pettit presented the Zap-CHO performance results during the technical workshop and he also presented during the poster session at PEACe on Tuesday. Copies of the poster and presentation are available by contacting InVitria at the email address or phone number listed below.

Zap-CHO is a next generation media supplement that delivers consistent cell culture performance. Previously, only FBS could deliver equivalent performance, but safety concerns of a fetal bovine component in cell culture media forced many customers away from this component. In the last decade, customers have eliminated FBS in cell culture media only to lose cell culture performance. To regain the lost performance, many began adding hydrolysates to the media. However, hydrolysates introduced significant variability, leading to failed experiments and production failures. Zap-CHO addresses these concerns and provides significant benefits in CHO cell culture, including:

 
  • Faster cell line development and seed train expansion
  • Animal component-free media
  • Consistency of a defined media component
  • Biomanufacturing optimization and improved production economics
  • Better and more predictable performance in cell culture research and development

"Now, with Zap-CHO, customers can get the animal free benefit of hydrolysates, the performance of FBS and the consistency of a defined media," said Randy Semadeni, InVitria's Vice President of Business Development. "It is a new era for the cell culture industry."

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria's products or to obtain a copy of Dr. Pettit's Zap-CHO poster or presentation, please contact InVitria at 1-800-916-8311.

###

Read the full story at http://www.prweb.com/releases/Zap-CHO/PEACe/prweb2928524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
2. InVitria Cell Culture Product Line to Headline PEACe
3. InVitria Sponsors ESACT 2009 in Dublin, Ireland
4. InVitria to Present at BIO 2009 International Convention in Atlanta
5. InVitria Reveals Technology to Optimize Hybridoma Production Performance
6. InVitria Headlines Sponsorship of WilBio's Waterside Conference
7. InVitria Announces Launch of Recombinant Albumin for Diagnostics
8. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
9. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
10. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
11. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , ... January 19, 2017 , ... ... by the American Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. ... Institutes of Health, Dr. Li completed his internship in internal medicine at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, Carol ... that resulted in severe facial disfiguration. After four frightening years of isolation and ... UCLA Medical Center, who removed the substances in a partial facial transplant through ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
(Date:1/19/2017)... ... , ... Sam & Associates Insurance Agency, a full service firm providing asset ... Bay Area, is launching a charity drive to raise awareness of heart disease risk ... primary killer of adult men and women in America, and is responsible for over ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric Medical ... developing medical devices for children. The Consortium chose ... seed grants of $50,000 each. The devices under ... nerve signals, a hand-operated rapid blood delivery system for emergency ... babies. ...
(Date:1/18/2017)...   Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to restore ... the Company,s operating results for 2016 and an outline ... Company described in its recent 10-K filing with the ... The Company,s contract laboratory completed its evaluation of NovaDerm┬«, ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: